Posting: # 18726
I have conducted a full replicate BE study for one of the highly variable product for Europe regulatory.
Based on the reference product variability, relaxed 90% Confidence Intervals is 75.18 to 133.01 for Cmax.
Study marginally failed with 90% upper CI data of 133.18
Is there any way to justify Europe regulatory authority(ies) to accept this study data? (DCP submission)
Edit: Category changed; see also this post #1 and #4. [Helmut]
Posting: # 18727
1. Emissions for R-R are not considered and, therefore, it is possible that equivalence limits can be reduced.
2. Do not assessed the alpha and size of CI may be greater than the 90% CI.
Those. It may be more significant difference than it seems.
Posting: # 18743
please give complete information: Sample size (if unbalanced: number of subjects per sequences), observed GMR, and 90% CI. Was it a 4-period (TRTR|RTRT) or a 3-period (TRT|RTR) design? Target power and GMR assumed in study planning?
» […] relaxed 90% Confidence Intervals
You mean: Expanded (acceptance) limits</nitpick>
» Is there any way to justify Europe regulatory authority(ies) to accept this study data?
Are you talking about ‘bending the rules’ and convince them accepting it? Chances are pretty low (patient’s risk >0.05). Furthermore, some European statisticians are already aware of the potential inflation of Type I Error in reference-scaling, which might be the case with your CVwR of 38.9%.
The quality of responses received is directly proportional to the quality of the question asked. ☼